Here are 1-3 brief analogies to describe Korro Bio:

• Like a CRISPR Therapeutics, but focused on editing RNA instead of DNA.
• Similar to Alnylam Pharmaceuticals, but for editing RNA rather than silencing it.

• Genetic Medicines based on RNA Editing: Korro Bio is developing therapeutic candidates that utilize RNA editing technology to treat various rare and highly prevalent diseases.

Korro Bio (KRRO) is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of genetic medicines. At its current stage of operations, Korro Bio does not have commercialized products available for sale to end customers.

Therefore, Korro Bio does not currently have major customers, either other companies or individuals, that purchase its products or services.

Ram Aiyar, Ph.D., MBA Chief Executive Officer & President

Ram Aiyar brings nearly two decades of diverse experience in biotech and pharma, covering all stages of development from launch to clinical to commercialization. He was a co-founder, chief financial officer, and chief business officer at Corvidia Therapeutics, where he notably led its acquisition by Novo Nordisk for $2.1 billion. Before Corvidia, he served as an entrepreneur-in-residence at BioHealth Innovation (BHI) and held leadership roles in corporate development, finance, and strategy at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase. His scientific career began in research at Janssen Pharmaceuticals' immunology group.

Vineet Agarwal Chief Financial Officer

Vineet Agarwal was appointed Chief Financial Officer of Korro Bio in May 2021. He joined the company from J.P. Morgan Chase & Co., where he was a Senior Executive Director in the Healthcare Investment banking group, bringing over 14 years of leadership experience with biopharma companies. At J.P. Morgan, he advised clients on crucial financings, including private placements, initial public offerings (IPOs), special purpose acquisition companies (SPACs), equity offerings, and convertible debt deals, as well as strategic transactions such as acquisitions, mergers, and licensing. He began his career with J.P. Morgan in 2007.

Loic Vincent, Ph.D. Chief Scientific Officer

Loic Vincent serves as the Chief Scientific Officer at Korro Bio.

Todd Chappell, MBA Chief Operating Officer

Todd Chappell holds the position of Chief Operating Officer at Korro Bio.

Stephanie Engels Chief People Officer

Stephanie Engels was appointed Senior Vice President, Head of People and Culture in November 2022 (currently Chief People Officer). She contributes extensive expertise in building and scaling learning organizations to the team.

Korro Bio (KRRO), a biopharmaceutical company specializing in RNA editing for genetic medicines, faces several key risks inherent to its stage of development and the innovative nature of its technology.

The most significant risks to Korro Bio's business are:

1. Clinical Trial Failure and Regulatory Uncertainty: As an early-stage biotechnology company, Korro Bio's success hinges on the efficacy and safety of its product candidates, which have yet to be definitively proven in human trials. The company experienced a significant setback with its lead drug candidate, KRRO-110, which failed to achieve anticipated levels of functional protein in early-stage clinical trials, leading to an approximate 78% plunge in stock value and a shift in development strategy. Such outcomes underscore the inherent risks in biopharmaceutical development. Furthermore, the regulatory landscape for novel gene editing technologies like RNA editing remains uncertain, and any changes in requirements or delays in the approval process could negatively impact the company's timelines and financial position. The use of oligonucleotides, considered a relatively new class of drugs, increases the risk that clinical trial outcomes may not be sufficient to secure regulatory approval.

2. Financial Sustainability and Significant Cash Burn: Korro Bio has consistently incurred substantial losses since its inception and is projected to continue doing so for the foreseeable future, making profitability uncertain. The company is pre-revenue and rapidly depleting its cash reserves. Despite implementing cost-saving measures, including a 34% workforce reduction, Korro Bio's financial health is considered moderate, with an Altman Z-Score indicating a potential risk of bankruptcy within the next two years. The company's cash runway, even with these reductions, is projected to extend only into the second half of 2027 or 2028. Further clinical setbacks would likely necessitate additional fundraising, potentially leading to significant dilution for existing shareholders.

3. Intellectual Property Protection and Market Differentiation: Given its focus on novel genetic medicines, Korro Bio's ability to obtain, protect, and defend its intellectual property rights is critical for the development and commercialization of its product candidates. Failure to adequately secure these rights could severely impede its business. The highly competitive nature of the biotechnology sector, particularly in gene editing, means that the emergence of rival products or technologies could adversely affect Korro Bio's competitive position. Concerns regarding differentiation have also arisen as Korro Bio has pivoted its delivery strategy, adopting an approach used by some rivals, which may challenge its unique market proposition.

Korro Bio (NASDAQ: KRRO) is a biopharmaceutical company focused on developing genetic medicines based on editing RNA for various diseases.

Here are the addressable markets for Korro Bio's main pipeline programs:

• Alpha-1 Antitrypsin Deficiency (AATD): Korro Bio's lead program, KRRO-121 (a GalNAc-conjugated version following an earlier candidate, KRRO-110), targets Alpha-1 Antitrypsin Deficiency. This rare genetic disorder affects an estimated 200,000 patients in the U.S. and E.U., representing a market opportunity of approximately $3 billion. The program has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency.
• Hyperammonemia in Urea Cycle Disorders and Hepatic Encephalopathy: Korro Bio has nominated KRRO-121 as a development candidate for hyperammonemia in urea cycle disorders and hepatic encephalopathy. This program involves a GalNAc-conjugated oligonucleotide designed to generate a stabilized enzyme for ammonia clearance. The addressable market size in dollar figures for this specific indication is not explicitly provided in the available information.
• Longevity, Liver Health, and Amyotrophic Lateral Sclerosis (ALS): Korro Bio is also engaged in preclinical work for programs in longevity, liver health, and ALS. For ALS, the company is developing oligonucleotides targeting the mRNA for TAR DNA binding protein 43 (TDP-43). ALS is considered a rare disease by the FDA and EMA. For liver health, a GalNAc-conjugated oligonucleotide is being developed to improve liver function. Specific addressable market sizes in dollar figures for these preclinical programs are not explicitly provided in the available information.
• Cardiometabolic Diseases: Korro Bio has a strategic collaboration with Novo Nordisk focused on cardiometabolic diseases. This collaboration has potential milestone payments of up to $530 million. The specific addressable market size in dollar figures for the cardiometabolic program is not explicitly provided in the available information.

1. Advancement and Potential Commercialization of KRRO-121 for Hyperammonemia: Korro Bio has nominated KRRO-121 as a development candidate for treating hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). A regulatory submission for KRRO-121 is anticipated in the second half of 2026. This program is considered to have blockbuster potential in multiple indications and is designed to activate a biological pathway by creating a de novo protein variant. Successful clinical development and eventual commercialization of KRRO-121 would represent a significant new revenue stream.
2. Advancement and Potential Commercialization of the GalNAc-conjugated Alpha-1 Antitrypsin Deficiency (AATD) Program: Following insights from its KRRO-110 program, Korro Bio is strategically pivoting to a new GalNAc-conjugated oligonucleotide for Alpha-1 Antitrypsin Deficiency (AATD), with a development candidate nomination expected in the second quarter of 2026. This approach aims to restore therapeutic protein levels and address both lung and liver manifestations of AATD, a rare genetic disorder. Successful progression through clinical trials and market approval for this differentiated therapeutic option would drive future revenue.
3. Growth in Collaboration Revenue: Korro Bio currently generates collaboration revenue, which notably increased to $6.4 million in 2025 from $2.3 million in 2024. This includes revenue from a partnership with Novo Nordisk for cardiometabolic diseases. Further milestones achieved through existing collaborations or the establishment of new strategic partnerships could significantly contribute to revenue growth over the next 2-3 years, providing funding and potentially upfront payments or royalties.
4. Progression of the Broader RNA Editing Pipeline into Clinical Development: Beyond its lead candidates, Korro Bio is advancing a pipeline of wholly-owned programs and additional partnered programs (including the Novo Nordisk cardiometabolic program) towards clinical development, alongside preclinical work in areas like longevity, liver health, and Amyotrophic Lateral Sclerosis (ALS). The successful advancement of these programs into clinical stages within the next 2-3 years would expand the company's long-term commercial potential and attract further investment or partnership opportunities, laying the groundwork for future product revenue.

Share Issuance

• Korro Bio secured a private investment in public equity (PIPE) financing, anticipated to close around March 10, 2026, which is expected to generate approximately $85 million in gross proceeds.
• As part of this PIPE financing, Korro is selling 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for 3,148,836 additional shares at $11.109 per warrant.
• The company's diluted shares outstanding increased to 9.392 million for the period ending September 30, 2025, reflecting an increase of 0.95% from the prior year.

Inbound Investments

• Korro Bio completed an oversubscribed $85 million private placement financing, led by Venrock Healthcare Capital Partners, with significant participation from a mix of new and existing institutional investors.
• This substantial financing is projected to extend Korro Bio's cash runway into the second half of 2028.
• Various major shareholders and investors, including Enterprise Associates 17 New, collectively purchased over $2.3 million in Korro Bio stock in March 2026.

Capital Expenditures

• Korro Bio expects that its existing cash, cash equivalents, marketable securities, and the proceeds from the March 2026 private placement financing will cover its operating expenses and capital expenditure requirements into the second half of 2028.
• In the most recent reported quarter, capital expenditures totaled -$0.084 million USD.
• Historical data indicates capital expenditures (PPE Investments) were -$17.902 million, -$7.836 million, and -$5.136 million in recent fiscal periods.